Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 4/20 | 0.31 |
| ▸ | PDK4 | Q16654 | 3/20 | 0.31 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1990993 | 1.00 | CHRNB2 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA4PADI4 | |
| SCHEMBL1989217 | 0.84 | PADI4 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA4PADI4 | |
| SCHEMBL1989220 | 0.84 | PADI4 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA4PADI4 | |
| SCHEMBL1992376 | 0.84 | PADI4 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA4PADI4 | |
| SCHEMBL1990392 | 0.78 | SIGMAR1 (0.46) | PADI4 | |
| SCHEMBL1985618 | 0.78 | SIGMAR1 (0.46) | PADI4 | |
| SCHEMBL1985617 | 0.78 | SIGMAR1 (0.46) | PADI4 | |
| SCHEMBL1985517 | 0.78 | SIGMAR1 (0.46) | PADI4 | |
| SCHEMBL1990395 | 0.78 | SIGMAR1 (0.46) | PADI4 | |
| SCHEMBL1985516 | 0.78 | SIGMAR1 (0.46) | PADI4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152248-A1 | BRIDGEHEAD AMINE RING-FUSED INDOLES AND INDOLINES | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | claimed |
| EP-2516440-B1 | BRIDGEHEAD AMINE RING-FUSED INDOLES AND INDOLINES USEFUL TO TREAT NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS | ABBVIE INC (US) | 2014-07-23 | — | — | EP | disclosed |
| US-8524703-B2 | Bridgehead amine ring-fused indoles and indolines | ABBVIE INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20110152248-A1 | BRIDGEHEAD AMINE RING-FUSED INDOLES AND INDOLINES | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152248-A1 | BRIDGEHEAD AMINE RING-FUSED INDOLES AND INDOLINES | IDO2, IDO1, TPH2 | CHRNB2 522/4885CHRNB4 815/4885CHRNA3 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.